AGIO
Agios Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$33.10
−0.09%0
Insider buys (3m)
2
Insider sells (3m)
-$1.1M
Net value (3m)
+17.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 6, 2026 | Gheuens Sarah · officer: Chief Medical Officer | Sale | 30,000 | $30 |
| Jul 10, 2026 | Backstrom Jay T. · director | M-Exempt | 1,447 | $0.00 |
| Jul 10, 2026 | Backstrom Jay T. · director | A-Award | 1,447 | $0.00 |
| Jul 2, 2026 | Gheuens Sarah · officer: Chief Medical Officer | Sale | 4,007 | $38 |
| Jul 2, 2026 | Gheuens Sarah · officer: Chief Medical Officer | M-Exempt | 8,375 | $0.00 |
| Jun 23, 2026 | Scadden David · director | M-Exempt | 2,816 | $0.00 |
| Jun 23, 2026 | Smith Cynthia · director | M-Exempt | 2,816 | $0.00 |
| Jun 23, 2026 | Viswanadhan Krishnan · officer: Chief Strategy and Operations | A-Award | 3,000 | $0.00 |
| Jun 23, 2026 | Foster-Cheek Kaye I · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | FOUSE JACQUALYN A · director | A-Award | 2,927 | $0.00 |
| Jun 23, 2026 | Scadden David · director | A-Award | 2,927 | $0.00 |
| Jun 23, 2026 | Jones Cecilia · officer: Chief Financial Officer | M-Exempt | 3,000 | $0.00 |
| Jun 23, 2026 | Foster-Cheek Kaye I · director | M-Exempt | 2,816 | $0.00 |
| Jun 23, 2026 | Milanova Tsveta · officer: Chief Commercial Officer | A-Award | 3,000 | $0.00 |
| Jun 23, 2026 | Goff Brian · director, officer: Chief Executive Officer | A-Award | 39,000 | $0.00 |
| Jun 23, 2026 | Viswanadhan Krishnan · officer: Chief Strategy and Operations | M-Exempt | 3,000 | $0.00 |
| Jun 23, 2026 | Gheuens Sarah · officer: Chief Medical Officer | M-Exempt | 3,000 | $0.00 |
| Jun 23, 2026 | Goff Brian · director, officer: Chief Executive Officer | M-Exempt | 39,000 | $0.00 |
| Jun 23, 2026 | Foster-Cheek Kaye I · director | A-Award | 2,927 | $0.00 |
| Jun 23, 2026 | Ho Maykin · director | A-Award | 2,927 | $0.00 |
| Jun 23, 2026 | Jones Cecilia · officer: Chief Financial Officer | A-Award | 3,000 | $0.00 |
| Jun 23, 2026 | Burns James William · officer: Chief Legal Officer | A-Award | 3,000 | $0.00 |
| Jun 23, 2026 | Scadden David · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | Ho Maykin · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | FOUSE JACQUALYN A · director | M-Exempt | 2,816 | $0.00 |
| Jun 23, 2026 | Backstrom Jay T. · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | Ballal Rahul D. · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | Smith Cynthia · director | A-Award | 14,950 | $34 |
| Jun 23, 2026 | Gheuens Sarah · officer: Chief Medical Officer | A-Award | 3,000 | $0.00 |
| Jun 23, 2026 | Smith Cynthia · director | A-Award | 2,927 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 73Increased 180Reduced 151Sold out 32
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 6,455,997 | Aug 7, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 5,917,400 | Aug 14, 2026 |
| ARMISTICE CAPITAL, LLC | Reduced | 5,916,000 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 5,754,957 | May 13, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 5,684,000 | May 15, 2026 |
| ARMISTICE CAPITAL, LLC | Reduced | 5,210,000 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 3,533,633 | Aug 7, 2026 |
| Lynx1 Capital Management LP | Increased | 3,408,937 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 3,364,879 | May 15, 2026 |
| D. E. Shaw & Co., Inc. | Increased | 3,107,005 | Aug 14, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 2,898,197 | Aug 13, 2026 |
| ERSTE ASSET MANAGEMENT GMBH | Reduced | 2,704,900 | May 11, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,681,845 | Aug 13, 2026 |
| D. E. SHAW & CO., INC. | Increased | 2,681,169 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,632,316 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 6, 2026